Status:
RECRUITING
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Age-Related Macular Degeneration
Diabetic Macular Edema
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD, DME or RVO in adults. It will also learn about the safety of drug Faricimab. The main questions it aims to answer are...
Detailed Description
Intravitreal anti-vascular endothelial growth factor (VEGF) therapies are used to treat retinal vascular diseases such as neovascular (wet) age-related macular degeneration (nAMD), diabetic macular ed...
Eligibility Criteria
Inclusion
- Chinese patients aged 18 years or older and of any gender;
- Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;
- Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;
- Patients who have received at least one treatment with faricimab during the course of the study;
- have signed an informed consent form.
Exclusion
- Active ocular inflammation or suspected active ocular infection in either eye;
- Receipt of any other anti-VEGF therapy after faricimab;
- Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection;
- Currently participating in any other clinical trial.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06572553
Start Date
March 1 2024
End Date
August 31 2024
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hanzhou, Zhejiang, China, 310000